eftilagimod alpha,pembrolizumab
immutep,merck
['tacti-002', 'melanoma', 'eftilagimod', 'pembrolizumab']
after hearing about tacti-002 just now at #asco22, continue exploring lag-3 in this popular #jitc article: eftilagimod alpha, a soluble lymphocyte activation gene-3 (lag-3) protein plus pembrolizumab in patients with metastatic melanoma 
#JITC is the official journal of @SITCancer, covering all aspects of tumor immunology and cancer immunotherapy. Editor-in-Chief: Pedro J. Romero, MD.